All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Amisulpride
Therapeutic Area: Gastroenterology Product Name: Barhemsys
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $23.5 million Upfront Cash: Undisclosed
Deal Type: Financing February 18, 2021
Details:
The net proceeds of the Placing are intended to be used To meet its sales force and marketing costs relating to BARHEMSYS® and BYFAVO™ including brand development and engagement with key opinion leaders, healthcare professionals and medical conference and speaker programs.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Amisulpride
Therapeutic Area: Gastroenterology Product Name: Barhemsys
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Cosmo Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing October 09, 2020
Details:
The Company plans to deploy this capital to support its ongoing US launches of BARHEMSYS® (amisulpride injection) for postoperative nausea & vomiting and BYFAVO™ (remimazolam for injection) for procedural sedation.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Naloxegol Oxalate
Therapeutic Area: Gastroenterology Product Name: Moventig
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: RedHill Biopharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 08, 2020
Details:
RedHill Biopharma has gained the rights to Movantik (naloxegol)1 in Israel from AstraZeneca. RedHill now holds the worldwide rights to Movantik, excluding Europe and Canada. RedHill to evaluate partnering opportunities for commercialization of Movantik in Israel.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Amisulpride
Therapeutic Area: Gastroenterology Product Name: Barhemsys
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2020
Details:
BARHEMSYS® (amisulpride injection) has been launched and is now commercially available in the US for order and delivery to customers through major wholesalers and specialty distributors.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Naloxegol Oxalate
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: RedHill Biopharma
Deal Size: $67.5 million Upfront Cash: $52.5 million
Deal Type: Divestment April 02, 2020
Details:
In 2015, AstraZeneca entered into a co-commercialisation agreement with Daiichi Sankyo, Inc. for Movantik in the US, which has now been transferred to RedHill.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
